
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics Inc. has demonstrated a robust safety profile for its lead candidates WTX-330 and WTX-124, with manageable treatment-emergent adverse events that are primarily mild to moderate, which supports a favorable outlook for further clinical development. The company's proprietary PREDATOR platform offers a novel approach to cancer treatment by designing conditionally activated molecules, which not only enhance safety and efficacy but also improve dosing flexibility, thereby expanding potential therapeutic applications beyond oncology. Additionally, encouraging preclinical results, including promising monotherapy activity and response rates in various cancer types, highlight the potential for Werewolf's therapeutics to address significant limitations of current treatments in the market.
Bears say
Werewolf Therapeutics encountered a significant net loss of $20.4 million in the fourth quarter of 2024, which represented an increase from $12.0 million in the same period the previous year, indicating potential financial distress. There are notable risks associated with the company's lead candidate WTX-124, including possible clinical or regulatory setbacks, and concerns regarding its ability to achieve acceptable safety and efficacy profiles, which could hinder its market potential. Additionally, the company’s expansion opportunities may not be adequately valued by the market, contributing to an overall negative sentiment surrounding its financial outlook.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares